$0.31
0.00% yesterday
Nasdaq, Nov 25, 10:12 pm CET
ISIN
US03835L1089
Symbol
APVO
Sector
Industry

Aptevo Therapeutics Inc Stock price

$0.31
+0.06 25.49% 1M
-0.40 56.72% 6M
-7.66 96.14% YTD
-7.80 96.21% 1Y
-525.49 99.94% 3Y
-389.00 99.92% 5Y
-4,927.69 99.99% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.00 0.00%
ISIN
US03835L1089
Symbol
APVO
Sector
Industry

Key metrics

Market capitalization $5.70m
Enterprise Value $2.78m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.19
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-24.60m
Free Cash Flow (TTM) Free Cash Flow $-23.28m
Cash position $7.75m
EPS (TTM) EPS $-25.45
Short interest 8.95%
Show more

Is Aptevo Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Aptevo Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aptevo Therapeutics Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aptevo Therapeutics Inc:

Buy
100%

Financial data from Aptevo Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.31 0.31
49% 49%
-
- -
-
-
- Selling and Administrative Expenses 11 11
8% 8%
-
- Research and Development Expense 14 14
22% 22%
-
-24 -24
18% 18%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -25 -25
18% 18%
-
Net Profit -24 -24
47% 47%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aptevo Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aptevo Therapeutics Inc Stock News

Neutral
Accesswire
4 days ago
Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment SEATTLE, WA / ACCESSWIRE / November 22, 2024 / Aptevo Therapeutics (NASDAQ:APVO), a leader in the development of novel bispecific antibodies for cancer treatment, provided additional details about its robust oncology pipeline which is poised to potentially a...
Neutral
Accesswire
6 days ago
Potential to redefine frontline AML treatment being evaluated in clinic: Mipletamig, CD3 x CD123 bispecific, in combination with standard of care, offers a multi-mechanism strategy for potential improved patient outcomes Favorable early safety, efficacy, tolerability and durability of remission data informed Aptevo's ongoing RAINIER Phase 1b/2 trial SEATTLE, WA / ACCESSWIRE / November 20, 2024 ...
Neutral
Accesswire
15 days ago
Colon cancer patient achieved stable disease and remained on study for more than six months, breast cancer patient remained on study for more than 11 months Biomarker analysis confirms immune activation in the tumor microenvironment Data Presented at Society for Immunotherapy of Cancer on November 8, 2024 LUND, SWEDEN and SEATTLE, WA / ACCESSWIRE / November 11, 2024 / Alligator Bioscience AB ("...
More Aptevo Therapeutics Inc News

Company Profile

Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics to improve patients lives. Its pipeline includes APVO210, APVO436, ROR1 Candidate, and ALG.APV-527. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.

Head office United States
CEO Marvin White
Employees 40
Founded 2016
Website www.aptevotherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today